Browsing by Author "Evrensel, Türkkan"

Now showing 1 - 20 of 123

Adrenokortikal karsinomlu olgularımızın retrospektif değerlendirilmesi
(Uludağ Üniversitesi, 2007-06-06) Kanat, Özkan; Özal, Güze; Yener, Feyza; Evrensel, Türkkan; Kurt, Ender; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Tıbbi Onkoloji Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Adrenokortikal karsinom (AKK) nadir ve agresif bir tümor olup prognozu kötüdür. Bu çalışmada, AKK hastalarımızın klinik özellikleri ve tedavi sonuçları retrospektif olarak değerlendirildi. Departmanımızda, toplam sekiz AKK’lu hasta tedavi edildi. Hastaların tamamında metastaz mevcuttu. Hastalara etoposid, doksorubisin ve sisplatin (EAP) veya etoposid ve sisplatin (EP) rejimi uygulandı. Dört hastada stabil hastalık, diğer dört hastada ise progresyon olduğu gözlendi. Ortalama 7.7 aylık (3-15 ay) takipte 5 hasta progresif hastalık nedeniyle öldü. Bulgularımız AKK’un agresif doğasını yansıtmaktadır.
Akciğer kanserli hastalarda prognostik ve prediktif biyobelirteçlerin serum düzeylerinin incelenmesi
(Uludağ Üniversitesi, 2012) Coşkun, Belkıs Nihan; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
İleri evre akciğer kanserinde ortalama sağkalım süresi oldukça kısadır. Kanser tedavisinin etkinliğini erken dönemde saptamak, sağkalım için önemlidir.Sitokeratinler, epiteliyal hücrelerde yüksek düzeylerde bulunmakta, serumda ölçülebilmektedir. Onkojenik transformasyondan sonra bu ekspresyon devam etmekte hatta artmaktadır. Hücre ölümü belirteçleri olan M30 (Apoptoz belirteci) ve M65 (Nekroz belirteci) antijenlerinin birçok kanser türünde prognozda ve kanser tedavisine cevabı değerlendirmede önemli belirteçler olduğu bilinmektedir.Bu çalışmaya, potansiyel rezektabıl akciğer kanseri tanılı 48 hasta, 38 sağlıklı kontrol grubu dahil edilmiştir. Hastaların 43'ünde kemoterapi öncesi ve kemoterapiden 48 saat sonra serum M30, M65 seviyeleri çalışılmıştır. Kanserli hastalarda, sağlıklı kontrol grubuna göre tedavi öncesi serum M30, M65 seviyelerinin istatistiksel olarak anlamlı (p<0.001 ve p<0.05) derecede yüksek olduğu görülmüştür. Kemoterapi sonrası her iki belirteç de tedavi öncesine oranla anlamlı derecede yükselmiştir (p<0.001).Tedaviye yanıt veren hastalarda (n=28) M30 değerinin %34 arttığı, M65 değerinin ise %68 arttığı görüldü. Progrese olan hastalarda (n=12) M30 değerinin % 78 arttığı, M65 değerinin ise %54 arttığı görüldü. Hastaların yüzde değişimi göz önüne alındığında tedaviye cevap veren ve vermeyenlerin M30, M65 düzeyleri karşılaştırıldığında M65 değerlerinde farklılık saptanmazken, progrese olan hastalarda M30 değerinin anlamlı olarak arttığı saptandı (p=0.694, p<0.05).Sonuç olarak, akciğer kanserli hastalar, belirgin yüksek M30, M65 seviyelerine sahiptir. Bu da M30, M65 antijenlerinin prediktif marker olarak kullanılabileceğini düşündürmektedir. Tedaviye yanıt veren hastalarda M65 seviyeleri daha çok artarken, tedaviye yanıt vermeyenlerde M30 seviyeleri daha çok artmıştır. Bu artış istatistiksel olarak anlamlı olmamakla birlikte;yalnızca apoptozun değil, total hücre ölümünün (apoptoz + nekroz) ölçülmesi, taksan-bazlı kemoterapiye yanıt hakkında daha iyi bir fikir sağlayabilir.
Alterations of MiRNA expression in early-onset Turkish colorectal cancer patients' tumor tissues
(Elsevier, 2012-07) Zorluoğlu, Abdullah; Ak, Seçil; Tunca, Berrin; Çeçener, Gülşah; Egeli, Ünal; Tezcan, Gülçin; Yılmazlar, Tuncay; Öztürk, Elif; Yerci, Ömer; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-1619-6680; 0000-0002-9732-5340; F-8554-2017; ABI-6078-2020; AAH-3843-2020; AAH-3847-2021; AAJ-1027-2021
Association and prognostic significance of the functional-1562C/T polymorphism in the promoter region of MMP-9 in Turkish patients with gastric cancer
(Frontiers Media, 2015-09-28) Avcı, Nilüfer; Çubukçu, Erdem; Ölmez, Ömer Fatih; Türe, Mehmet; Deligönül, Adem; Şahintürk, Serdar; Topak, Ali; Kurt, Ender; Evrensel, Türkkan; Şahin, Ahmet Bilgehan; Yakut, Tahsin; Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı.; 0000-0002-7612-0055; 0000-0002-9732-5340; 0000-0002-7846-0870; ECY-8582-2022; ESM-4544-2022; ACQ-9887-2022; HOV-5404-2023; DAS-3088-2022; AAJ-1027-2021; AAM-4927-2020; GIS-1493-2022; 6602186133; 37088030300; 57214054591; 55313334700; 7006207332; 6603942124; 57188809248; 6602802424
Matrix metalloproteinases (MMPs) are a group of zinc-dependent peptidases that participate in matrix turnover in solid malignancies. The aim of this study was twofold. First, we sought to investigate under a case-control design the association between the functional -1562C/T polymorphism in the promoter region of MMP-9 and gastric cancer (GC) in a Turkish sample. Second, we examined its prognostic significance in GC patients. A total of 144 subjects were enrolled in the case-control study (79 GC cases and 65 controls). Overall survival (OS) and progression-free survival (PFS) served as the main outcome measures in the longitudinal study. The MMP-9 -1562C/T polymorphism was genotyped using a polymerase chain reaction-restriction fragment length polymorphism method. The odds ratio (OR) of GC for the CC genotype relative to the CT+TT genotypes was not significant (OR = 0.89, 95 % confidence interval [CI] = 0.44-1.82, P = 0.75). These results did not change after allowance for age and sex in multivariable regression analysis (OR = 0.81, 95 % CI = 0.40-1.94, P = 0.84). When the MMP-9 -1562C/T polymorphism was analyzed among GC patients in relation to OS and PFS, we found no significant differences between subjects with the CC and CT+TT genotypes. In conclusion, the results of our study did not point toward a major role of the MMP-9 -1562C/T polymorphism in the pathogenesis and clinical course of GC in Turkish subjects.
Association of breast cancer and cytokine gene polymorphism in Turkish women
(Saudi Medical Journal, 2007-11) Gönüllü, Güzin; Baştürk, Bilkay; Evrensel, Türkkan; Oral, Barbaros; Gözkaman, Ayşe; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Immünoloji Anabilim Dalı.; 6603942124; 7004498001; 9633205800; 6602587152
Objective: To investigate the association of cytokine gene polymorphism with the development of breast cancer. Methods: The study was carried out in Uludag University Medical School, Bursa, Turkey. The study included 38 patients with breast cancer admitted to the Medical Oncology outpatient clinic, and 24 healthy controls, age and sex matched, from the Internal Medicine Department between 2004 and 2005. All genotyping of tumor necrosis factor-cc (TNF-alpha), tumor growth factor-beta 1 (TGF-beta 1), interleukin (IL)-10, IL-6, and interferon-gamma (IFN-gamma) experiments were performed using polymerase chain reaction sequence-specific primers. Results: The frequencies of IL-6-174GC genotype and IL-10 (-1082, -819, -592) GCC/ATA haplotype were significantly higher in the patient group (p=0.0008) when compared with controls (p=0.020). Significantly lower frequencies of IL-10 (-1082,-819,-592) ACC/ATA haplotype were observed in the patient group in comparison to the controls (p=0.026). The distribution of IFN-gamma +874, TNF-a 308, and TGF-beta 1 codon 10-25 genotypes failed to show any statistical significant association with the development of breast cancer. Conclusion: Our data suggest that IL-10 (-1082, -819, -592) GCC/ATA haplotype and IL-6-174 GC genotype seem to be potential risk factors for the development of breast cancer. The presence of IL-10ACC/ATA haplotype may be protective for the oncogenesis of breast cancer.
Biosimilar filgrastim vs filgrastim: A multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
(Dove Medical Press, 2018) Sevinç, Alper; Özkan, Metin; Özet, Ahmet; Dane, Faysal; Öksüzoğlu, Berna; Işıkdoğan, Abdurrahman; Özdemir, Feyyaz; Uncu, Doğan; Gümüş, Mahmut; Yaren, Arzu; Kara, Oğuz; Tekin, Salim Başol; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; 6603942124
Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia. Patients and methods: This multicenter, observational study was conducted at 14 centers. The study included 337 patients experiencing neutropenia under chemotherapy. Patients were given either filgrastim 30 MIU or 48 MIU (Neupogen (R)) or biosimilar filgrastim 30 MIU (Leucostim (R)). Data regarding age, chemotherapeutic agents used, number of chemotherapy courses, previous diagnosis of neutropenia, neutrophil count of patients after treatment, medications used for the treatment of neutropenia, and duration of neutropenia were collected. Time to absolute neutrophil count (ANC) recovery was the primary efficacy measure. Results: Ambulatory and hospitalized patients comprised 11.3% and 45.1% of the enrolled patients, respectively, and a previous diagnosis of neutropenia was reported in 49.3% of the patients, as well. Neutropenia occurred in 13.7% (n=41), 45.5% (n=136), 27.4% (n=82), 11.4% (n=34), and 2.0% (n=6) of the patients during the first, second, third, fourth, and fifth cycles of chemotherapy, respectively. While the mean neutrophil count was 0.53 +/- 0.48 before treatment, a significant increase to 2.44 +/- 0.66 was observed after treatment (p=0.0001). While 90.3% of patients had a neutrophil count,1.49 before treatment, all patients had a neutrophil count >= 1.50 after treatment. Neutropenia resolved within <= 4 days of filgrastim therapy in 60.1%, 56.7%, and 52.6% of the patients receiving biosimilar filgrastim 30 MIU, original filgrastim 30 MIU, and original filgrastim 48 MIU, respectively. However, there was no significant difference between the three arms (p=0.468). Similarly, time to ANC recovery was comparable between the treatment arms (p=0.332). Conclusion: The results indicate that original filgrastim and biosimilar filgrastim have comparable efficacy in treating neutropenia. Biosimilar filgrastim provides a valuable alternative; however, there is need for further studies comparing the two products in different patient subpopulations.
BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients
(Taylor & Francis Inc, 2014-10-01) Çeçener, Gülşah; Egeli, Ünal; Tunca, Berrin; Ertürk, Elif; Ak, Seçil; Gökgöz, Şehsuvar; Taşdelen, İsmet; Tezcan, Gülçin; Demirdoğen, Elif; Bayram, Nuran; Avcı, Nilüfer; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı; Uludağ Üniversitesi/İktisadi ve İdari Bilimler Fakültesi/Ekonometri Anabilim Dalı; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1619-6680; 0000-0002-3760-9755; 0000-0002-5956-8755; F-8554-2017; AAH-3843-2020; ABI-6078-2020; AAP-9988-2020; AAK-3371-2021; ADM-8457-2022; AAJ-1027-2021; JFK-4021-2023; AAH-1420-2021; JQI-3400-2023; JDE-9426-2023; EXK-4525-2022; EBN-1186-2022; ERW-8812-2022; CCT-7946-2022
BRCA1/BRCA2 genes were screened in 117 patients with breast cancer by sequencing. Fourteen percent of patients tested positive for BRCA1/BRCA2 mutations. Four frame shift mutations, four pathogenic missense mutations, and 25 different sequence variations were detected. BRCA mutation positivity was significantly associated with Ki67 (p =.001). BRCA protein expressions were decreased in the patients harboring important mutations and polymorphisms (BRCA1; P508stop, V1740G, Q1182R, Q1756P and BRCA2; V2466A) related with disease. Our findings contribute significantly to the types of germline BRCA1/BRCA2 mutations and their biological effects in Turkish women. These data could help guide the management of BRCA1/BRCA2 mutation-carrying patients when considering breast-conserving therapy.
C-kit (CD117) expression in patients with small cell lung cancer
(Galenos Yayıncılık, 2015-03-01) Gözkaman, Ayşe; Okuturlar, Yıldız; Kanat, Özkan; Günald, Meral; Serin, Sibel Ocak; Saraydaroğlu, Özlem; Kumbasar, A. Baki; Evrensel, Türkkan; Gözkaman, Ayşe; Okuturlar, Yıldız; Kanat, Özkan; Serin, Sibel Ocak; SARAYDAROĞLU, ÖZLEM; EVRENSEL, TÜRKKAN; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Onkoloji Bilim Dalı.; ludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Z-1463-2018; AAJ-1027-2021; X-3647-2018; AAH-9701-2021; JRQ-2583-2023; JRU-4028-2023; DQW-9819-2022
Aim: The tyrosine-kinase receptor c-kit and its ligand stem cell factor (SCF) are coexpressed in many small cell lung cancer (SCLC) cell lines. The aim of this study was to search the role of CD117 (c-kit) overexpression as a prognostic marker in SCLC.Methods: Demographic and clinical data of patients with SCLC was registered. C-kit overexpression was evaluated using immunohistochemistry performed in paraffin-embedded specimens. Immunostaining data of 87 patients were correlated with survival and other relevant clinical parameters.Results: The mean age of the patients was 57.1 +/- 9.9 years. Thirty-nine patients (44.8%) had limited disease and 48 patients (55.2%) had extensive disease. C-kit (+) expression was observed in 24.1% of 87 patients. The mean survival time for c-kit (+) patients was 10.2 (CI=5.7-14.7) months as compared with the c-kit (-) population in whom the survival was 14.7 (CI=10.7-18.6) months. The difference in survival time between c-kit (+) and (-) patients was not statistically significant (p=0.264).Conclusion: New prognostic markers and more effective treatment regimens are needed for SCLC. Our findings may provide an insight to future clinical trials searching c-kit inhibitors in SCLC.
Capecitabine-induced cardiotoxicity mimicking myocardial infarction
(Bohn Stafleu van Loghum, 2009-08) Şentürk, Tunay; Kanat, Özkan; Evrensel, Türkkan; Aydınlar, Ali; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-8974-8837; C-1517-2017; AAI-6632-2021; 8342098300; 55881548500; 6603942124; 6603131517
Capecitabine, a fluoropyrimidine derivative, is an orally administered drug that delivers 5-fluorouracil (5-FU) selectively to the tumour. The drug has demonstrated activity in metastatic colorectal cancer. We describe a male patient receiving capecitabine therapy with typical chest pain and electrocardiographic changes consistent with ST-segment elevation myocardial infarction. Capecitabine-induced cardiotoxicity may develop in patients who have had a previous episode of 5-FU-induced cardiotoxicity. Capecitabine-induced cardiotoxicity is a rare condition that may lead to diagnostic and therapeutic dilemmas.
A case of primary spinal intramedullary lymphoma
(Elsevier Science, 2001-05) Bekar, Ahmet; Cordan, Teoman; Evrensel, Türkkan; Tolunay, Şahsene; Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Bilimler Bölümü/Tıbbi Patoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; 6603677218; 7801648865; 6603942124; 15745843100
A 41-year-old male presented to our clinic with a 1-month history of left hemiparesis. He had marked left arm weakness. The diagnostic work-up revealed an intramedullary mass at spinal level C2-4. Laminectomies were performed at C2-3-4 and the tumor was subtotally resected. Histological examination identified the mass as a non-Hodgkin's diffuse B-cell lymphoma. The patient was treated with corticosteroids, chemotherapy, and adjuvant radiotherapy. The residual tumor tissue had completely disappeared by 6 months of follow-up; however, the patient presented with intraventricular metastasis at 11 months postsurgery.
Cervical spine involvement in metastatic colorectal carcinomas: Should we think about an alternative route of metastasis other than Batson's plexus
(Elsevier, 1999) Orhan, Bülent; Manavoǧlu, Osman; Evrensel, Türkkan; Kurt, Ender; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; 6701877552; 6602587152; 6603942124; 7006207332
Chemo-immunotherapy with atezolizumab in extensive-stage small-cell lung cancer; single-center experience
(Akad Doktorlar Yayınevi, 2020-01-01) Şahin, Ahmet Bilgehan; Çubukcu, Erdem; Ocak, Birol; Deligönül, Adem; Kaçan, Turgut; Orhan, Sibel Oyucu; Evrensel, Türkkan; ŞAHİN, AHMET BİLGEHAN; ÇUBUKÇU, ERDEM; OCAK, BİROL; DELİGÖNÜL, ADEM; OYUCU ORHAN, SİBEL; EVRENSEL, TÜRKKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı; 0000-0002-7846-0870; 0000-0001-7537-1699; 0000-0001-8217-3471; 0000-0002-9732-5340; AAJ-8314-2021; AAJ-1027-2021; AAM-4927-2020; ETP-1691-2022; HHA-1866-2022; ESM-4544-2022
Chemo-immunotherapy (CIT) with platin, etoposide and monoclonal antibodies targeting the PD-1/PDL-1 pathway has recently improved survival in extensive-stage small-cell lung cancer (SCLC) after decades. We aimed to investigate the efficacy and safety of CIT with atezolizumab in extensive-stage SCLC in chemotherapy naive patients. Eleven patients who were treated and followed in our center were included in this retrospective observational study. All the patients received carboplatin, etoposide and atezolizumab in the induction phase and atezolizumab in the maintenance phase. The Kaplan-Meier test was used to determine progression-free survival (PFS) and overall survival (OS), and the effects of the sites of metastasis were analyzed using the log-rank test. The median age was 69.9 years, and 81.8% were male. The median number of CIT and total atezolizumab cycles was 4 and 7, respectively. 63.6% received maintenance therapy. Median PFS was 5.2 months (95% CI: 3.4-6.9), and median OS was 11.3 months (95% CI: 1.0-21.5). The overall response rate was 63.6%. There was no significant difference between patients with and without liver metastasis in terms of PFS and OS. We observed toxicity higher than grade 2 in more than half of the patients, and hematological toxicities were prominent. CIT with carboplatin, etoposide and atezolizumab is efficient and safe in extensive-stage SCLC considering the PFS, OS, response rates, 12-month survival rate, and side effects. The progression of liver lesions was remarkable. Cranial and thoracic radiation are issues that should be discussed in the future with data from clinical studies.
Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients
(Walter De Gruyter Gmbh, 2011-06) Ulukaya, Engin; Karaağaç, Esra Uğurlu; Arı, Ferda; Yılmaztepe, Arzu Oral; Balaban, Şaduman Adım; Tokullugil, Asuman Hatice; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/Klinik Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Fen-Edebiyat/ Biyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0003-0463-6818; 0000-0002-6729-7908; 0000-0002-9732-5340; A-5841-2017; K-5792-2018; AAG-7012-2021; AAJ-1027-2021; 6602927353; 14019915500; 24376085300; 23091316500; 15730076300; 6507662010; 6603942124
Background. Apoptosis is thought to be induced by chemotherapy in cancer patients. Therefore, the measurement of its amplitude may be a useful tool to predict the effectiveness of cancer treatment sooner than conventional methods do. Patients and methods. In the study presented, apoptosis was assessed with an ELISA-based assay in which caspase-cleaved cytokeratin 18 (M30-antigen), a novel specific biomarker of apoptosis, is measured. Thirty seven patients with malignant (nonmetastatic and metastatic) breast cancer, 35 patients with benign breast disease, and 34 healthy subjects were studied. Cancer patients received neoadjuvant chemotherapy consisting of either fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin plus docetaxel (ED). Apoptosis was detected before chemotherapy, 24 and 48 h after chemotherapy in the malignant group. Results. It was found that the baseline apoptosis level in either malignant but nonmetastatic group or benign group was not statistically different from that in the control group (p>0.05). However, it was statistically significantly higher in the metastatic group than that in the control group (p<0.05). Following the drug application, M30-antigen levels significantly increased at 24 h (p<0.05). The baseline M30-antigen levels increased about 3-times in patients showing tumor regression. Conclusions. M30-antigen level is increased after chemotherapy and its measurement may help clinicians to predict the effectiveness of chemotherapy sooner in breast cancer cases although confirmative larger trials are needed.
Cisplatin plus etoposide in advanced non-small cell lung cancer patients age of 70 years or older
(Elsevier, 2003-08-01) Kanat, Ozkan; Evrensel, Türkkan; Demiray, Mutlu; Kurt, Ender; Gönüllü, Güzin; Arslan, Murat; Manavoǧlu, Osman; Özkan, Hasan Atilla; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0003-2501-3097; 0000-0002-9732-5340; M-8060-2019; AAJ-1027-2021; 55881548500; 6603942124; 6603631569; 7006207332; 6506410014; 57197925370; 6602587152; 9250698600
Cisplatin plus etoposide in the adjuvant treatment of patients with non small cell lung cancer
(Derman Medical Publ, 2014-09-01) Çubukcu, Erdem; Canhoroz, Mustafa; Ölmez, Ömer Fatih; Kanat, Özkan; Kurt, Ender; Erol, Muharrem; Çubukcu, Sinem; Yorulmaz, Nadide; Bayram, Sami; Evrensel, Türkkan; Manavoğlu, Osman; ÇUBUKÇU, ERDEM; Canhoroz, Mustafa; Ölmez, Ömer Fatih; Kanat, Özkan; Kurt, Ender; Erol, Muharrem; ÇUBUKÇU, SİNEM; Yorulmaz, Nadide; BAYRAM, AHMET SAMİ; EVRENSEL, TÜRKKAN; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; JGT-4101-2023; CJW-6018-2022; DJG-4827-2022; CYM-0930-2022; DAS-3088-2022; JEN-3243-2023; JJB-0254-2023; GKI-1183-2022; EMY-5874-2022; AAJ-1027-2021; FLP-9613-2022
Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.
Cisplatin’e bağlı böbrek toksisitesi ve sentetik oral prostaglandin E1 analoğunun etkinliğinin değerlendirilmesi
(Uludağ Üniversitesi, 2002-09-30) Kurt, Ender; Evrensel, Türkkan; Gönüllü, Güzin; Kanat, Özkan; Demiray, Mutlu; Arslan, Murat; Ünlü, Özgür; Dilek, Kamil; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İstatistik Bilim Dalı.
Bir oral prostaglandin E1 analoğu olan misoprostolün steroid olmayan antienflamatuar ilaçlar (NSAID) ve siklosporin nefrotoksisitesinde protektif etkisi olduğu gösterilmesine karşın, cisplatin nefrotoksisitesindeki rolü incelenmemiştir. Çalışmamızda cisplatine bağlı gelişen akut böbrek yetmezliğinin ve misoprostolün akut cisplatin nefrotoksisitesindeki etkinliğinin incelenmesi amaçlanmıştır. Bu amaçla cisplatin+etoposid kemoterapi rejimi alması planlanan 28 akciğer kanserli hasta çalışmaya dahil edildi. Hastalar iki gruba ayrıldı. Misoprostol grubu kemoterapinin yanısıra çalışma süresince günde 4 kez 100 µg dozda misoprostol aldı. Kontrol grubu sadece kemoterapi aldı. Her iki grupta renal fonksiyonlar kemoterapi başlamasından önce ve kemoterapinin 2. ve 6. günlerinde değerlendirildi. Sonuç olarak, cisplatin kullanımına bağlı gelişen fonksiyonel bozukluklarda misoprostolün koruyucu etkinlik gösteremediği saptandı
CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer
(Sage Publications, 2012) Tunca, Berrin; Egeli, Ünal; Çeçener, Gülşah; Tezcan, Gülçin; Gökgöz, Şehsuvar; Taşdelen, İsmet; Bayram, Nuran; Tolunay, Şahsine; Umut, Görkem; Demirdöğen, Elif; Ertürk, Elif; Ak, Seçil; Çetintaş, Sibel; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; Uludağ Üniversitesi/İktisadi ve İdari Bilimler Fakültesi/Ekonometri Bölümü.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0001-5492-184X; 0000-0002-9732-5340; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1619-6680; 0000-0002-5956-8755; 0000-0002-9038-0515; 0000-0002-4483-9284; AAG-9068-2021; AAA-7047-2020; AAH-3843-2020; AAJ-1027-2021; AAP-9988-2020; AAH-1420-2021; ABI-6078-2020; AAI-1612-2021; F-8554-2017; 6602965754; 55665145000; 6508156530; 25650627600; 6603238737; 9637821500; 13609585600; 6602604390; 37058220200; 25644460900; 50261655300; 55253485700; 6505881756; 6603942124
Aims and background. The major cause of death in breast cancer patients is metastasis. Various biomarkers have been used for the early detection of circulating tumor cells in the peripheral blood of breast cancer patients. The aims of the current study were to analyze circulating tumor cells in the blood of breast cancer patients by investigating EGFR, CK19, CK20 and HER2 expression profiles and to evaluate their prognostic importance. Methods. CK19, CK20 and EGFR gene expression profiles were evaluated in the blood samples of 84 female patients with primary invasive ductal breast cancer and 20 healthy female volunteers using SYBR green-based real-time qPCR assays. HER2 expression analyses were conducted in 46 patients who had an HER2-positive primary tumor and in 30 healthy women to determine the cutoff level of positivity. Results. The positive rates of CK20, EGFR, CK19 and HER2 mRNA expression in the peripheral blood were 28.57% (24/84), 20.23% (17/84), 5.95% (5/84) and 2.17% (1/46), respectively. The high positive ratio of CK20 mRNA expression in the peripheral blood of breast cancer was identified for the first time in the current study. Significant differences were identified in CK20 expression status and several clinical parameters related with aggressiveness of tumors using a binary logistic regression analysis. Higher CK20-positive levels were observed in patients who had lymph node metastasis and advanced-grade primary tumors, which were estrogen receptor-negative. We have demonstrated that CK20 may be a novel biomarker that is useful to identify circulating tumor cells and predict breast cancer progression. Conclusions. The results suggest that the investigation of CK20 mRNA with other biomarkers in the peripheral blood of breast cancer patients may be useful to monitor the presence of disseminated tumor cells in the blood circulation and to predict the prognosis of breast cancer.
Clinical outcomes of lung metastasectomy in patients with colorectal cancer
(Baishideng Publishing Group, 2012-02-21) Ölmez, Ömer Fatih; Çubukçu, Erdem; Bayram, Ahmet Sami; Akçalı, Ünsal; Evrensel, Türkkan; Gebitekin, Cengiz; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; ABB-7580-2020; 26435400000; 53986153800; 8347194000; 16027743900; 6603942124; 6602156436
AIM: To investigate prognostic factors of survival following curative, non-palliative surgical removal of lung metastases secondary to colorectal cancer (CRC). METHODS: Between 1999 and 2009, a radical metastasectomy with curative intent was performed on lung metastases in 21 patients with CRC (15 male and 6 female; mean age: 57.4 +/- 11.8 years; age range: 29-74 years) who had already undergone primary tumour resection. RESULTS: The mean number of lung metastases ranged from one to five. The mean overall survival was 71 +/- 35 mo (median: 25 mo). After adjusting for potential confounders, multivariable Cox regression analyses predicted only the number of lung metastases (1 vs >= 2; hazard ratio: 7.60, 95% confidence interval: 1.18-17.2, P = 0.03) as an independent predictor of poor survival following lung resection for metastatic CRC. CONCLUSION: Resection of lung metastases is a safe and effective treatment in selected CRC patients with single lung metastases. (C) 2012 Baishideng. All rights reserved.
Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients
(Elsevier Science, 2019-10-14) Eskiler, Gamze Güney; Çeçener, Gülşah; Takanlou, Leila Sabour; Takanlou, Maryam Sabour; Egeli, Ünal; Aksoy, Seçil; Ünal, Ufuk; Tezcan, Havva; Eryılmaz, Işıl Ezgi; Gökgöz, Mustafa Şehsuvar; Tunca, Berrin; Çubukçu, Erdem; Evrensel, Türkkan; Çetintaş, Sibel; Taşdelen, İsmet; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji ve Genetik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-3760-9755; 0000-0003-4913-3616; 0000-0002-3316-316X; 0000-0002-1619-6680; 0000-0002-9732-5340; GGI-6227-2022; EAS-6830-2022; GYU-0252-2022; EWY-5692-2022; ETP-1691-2022; EOI-5652-2022; EBN-1186-2022; 6508156530; 57211585974; 57211582304; 55665145000; 57193933334; 57211584917; 57211580953; 57189380840; 57203870909; 6602965754; 53986153800; 6603942124; 6505881756; 9637821500
The aim of this study was to identify the frequency and spectrum of germline BRCA1/2 pathogenic alterations in a cohort of patients with breast carcinoma. In this study, a total of 603 breast cancer subjects from Turkey were screened for BRCA1/BRCA2 mutations using HDA and Sanger sequencing. In the present study, 21 BRCA1 and BRCA2 pathogenic variants were detected in 30 patients and BRCA1/2 mutations were significantly associated with a family history of breast/ovarian cancer. Analysis of overall survival for BRCA1/BRCA2 mutation carriers showed a trend for poor overall survival only in BRCA1 carriers, although this was not statistically significant in BRCA1 and BRCA2 mutation carriers. The c.5266dupC mutation is one of the most frequently reported mutations in BRCA1 and was identified in five breast cancer patients in our study. The most common BRCA2 gene mutations in the present study were c.8940delA and c.9097dupA, which were found in seven patients. We found mostly BRCA1 and BRCA2 mutation carriers in those patients who showed hormone-positive features. In conclusion, our data showed differences in the distribution of the mutation spectrum of BRCA1 and BRCA2 in Turkey.
Comparison of clinical outcomes of different erythropoietin usage strategies
(Sage Publications, 2004) Arslan, Murat; Evrensel, Türkkan; Kurt, Ender; Demiray, Mutlu; Gönüllü, Güzin; Kanat, Ozkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0003-2501-3097; M-8060-2019; 57197925370; 6603942124; 7006207332; 6603631569; 6506410014; 55881548500; 6602587152
Aim: There is no comprehensive study that compares the different usage strategies of recombinant human erythropoietin (rHuEPO) in platinum-induced anemia. In order to clarify this issue, we conducted a prospective clinical study. Material and methods: Seventy-seven patients were studied in three main groups. Group 1 (n = 17) consisted of cancer patients without anemia. These patients received rHuEPO starting from the first chemotherapy cycle. Group 2 (n = 26) consisted of patients whose hemoglobin (Hb) values decreased by at least 1 g/dL after the first cycle of chemotherapy. Group 3 (n = 34) consisted of patients whose Hb values dropped below 10.5 g/dL after the second chemotherapy cycle. Groups 2 and 3 were each divided into two subgroups. In groups 1, 2A and 3A rHuEPO (5000 U/day subcutaneously three times a week) treatment was continued until three weeks after the completion of chemotherapy. In groups 2B and 3B, rHuEPO was given for 12 weeks only. Results: There were no prominent differences between the Hb values of these groups throughout the chemotherapy cycles. Transfusion rates and the number of patients who became anemic were also not different between groups. Conclusion: No rHuEPO usage strategies are superior to others in terms of Hb levels and transfusion requirements. The decision as to when rHuEPO is to be added to platinum-containing therapy should be tailored to the health conditions of individual patients.